HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases.

Abstract
Modulation of aberrant cell cycle regulation is a potential therapeutic strategy applicable to a wide range of tumor types. JNJ-7706621 is a novel cell cycle inhibitor that showed potent inhibition of several cyclin-dependent kinases (CDK) and Aurora kinases and selectively blocked proliferation of tumor cells of various origins but was about 10-fold less effective at inhibiting normal human cell growth in vitro. In human cancer cells, treatment with JNJ-7706621 inhibited cell growth independent of p53, retinoblastoma, or P-glycoprotein status; activated apoptosis; and reduced colony formation. At low concentrations, JNJ-7706621 slowed the growth of cells and at higher concentrations induced cytotoxicity. Inhibition of CDK1 kinase activity, altered CDK1 phosphorylation status, and interference with downstream substrates such as retinoblastoma were also shown in human tumor cells following drug treatment. Flow cytometric analysis of DNA content showed that JNJ-7706621 delayed progression through G1 and arrested the cell cycle at the G2-M phase. Additional cellular effects due to inhibition of Aurora kinases included endoreduplication and inhibition of histone H3 phosphorylation. In a human tumor xenograft model, several intermittent dosing schedules were identified that produced significant antitumor activity. There was a direct correlation between total cumulative dose given and antitumor effect regardless of the dosing schedule. These results show the therapeutic potential of this novel cell cycle inhibitor and support clinical evaluation of JNJ-7706621.
AuthorsStuart Emanuel, Catherine A Rugg, Robert H Gruninger, Ronghui Lin, Angel Fuentes-Pesquera, Peter J Connolly, Steven K Wetter, Beth Hollister, Walter W Kruger, Cheryl Napier, Linda Jolliffe, Steven A Middleton
JournalCancer research (Cancer Res) Vol. 65 Issue 19 Pg. 9038-46 (Oct 1 2005) ISSN: 0008-5472 [Print] United States
PMID16204078 (Publication Type: Journal Article)
Chemical References
  • JNJ-7706621
  • Protein Kinase Inhibitors
  • Triazoles
  • Aurora Kinases
  • Protein-Serine-Threonine Kinases
  • Cyclin-Dependent Kinases
Topics
  • Animals
  • Aurora Kinases
  • Cell Line, Tumor
  • Cells, Cultured
  • Cyclin-Dependent Kinases (antagonists & inhibitors)
  • Endothelial Cells (drug effects, enzymology)
  • Female
  • HeLa Cells
  • Humans
  • Melanoma (drug therapy, enzymology)
  • Mice
  • Mice, Nude
  • Protein Kinase Inhibitors (pharmacology)
  • Protein-Serine-Threonine Kinases (antagonists & inhibitors)
  • Triazoles (pharmacology)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: